FIBROBIOLOGICS INC (FBLG) Stock Price, Forecast & Analysis
NASDAQ:FBLG • US31573L1052
FBLG Key Statistics, Chart & Performance
The current stock price of FBLG is 0.28 USD. In the past month the price decreased by -36.75%. In the past year, price decreased by -79.92%.
FBLG Technical Analysis
FBLG Financial Highlights
Over the last trailing twelve months FBLG reported a non-GAAP Earnings per Share(EPS) of -0.48. The EPS increased by 45.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -211.59% | ||
| ROE | -14800.8% | ||
| Debt/Equity | 36.58 |
FBLG Forecast & Estimates
9 analysts have analysed FBLG and the average price target is 7.14 USD. This implies a price increase of 2450% is expected in the next year compared to the current price of 0.28.
FBLG Ownership
FBLG Latest News, Press Relases and Analysis
FBLG Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.74 | 405.578B | ||
| AMGN | AMGEN INC | 16.87 | 204.31B | ||
| GILD | GILEAD SCIENCES INC | 16.57 | 185.891B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.02 | 122.042B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.72 | 83.206B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.48 | 43.51B | ||
| INSM | INSMED INC | N/A | 33.916B | ||
| NTRA | NATERA INC | N/A | 29.129B | ||
| BIIB | BIOGEN INC | 12.86 | 28.815B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.11 | 20.433B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About FBLG
Company Profile
FibroBiologics, Inc. engages in the development and commercialization of cell therapies. The company is headquartered in Houston, Texas and currently employs 13 full-time employees. The company went IPO on 2024-01-31. The firm is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. The company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
Company Info
FIBROBIOLOGICS INC
455 E. Medical Center Blvd, Suite 300
Houston TEXAS US
Employees: 13
Phone: 12816715150
FIBROBIOLOGICS INC / FBLG FAQ
Can you describe the business of FIBROBIOLOGICS INC?
FibroBiologics, Inc. engages in the development and commercialization of cell therapies. The company is headquartered in Houston, Texas and currently employs 13 full-time employees. The company went IPO on 2024-01-31. The firm is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. The company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
What is the stock price of FIBROBIOLOGICS INC today?
The current stock price of FBLG is 0.28 USD. The price increased by 12% in the last trading session.
Does FBLG stock pay dividends?
FBLG does not pay a dividend.
What is the ChartMill technical and fundamental rating of FBLG stock?
FBLG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Is FIBROBIOLOGICS INC (FBLG) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on FBLG.
What is the employee count for FBLG stock?
FIBROBIOLOGICS INC (FBLG) currently has 13 employees.
What is FIBROBIOLOGICS INC worth?
FIBROBIOLOGICS INC (FBLG) has a market capitalization of 18.63M USD. This makes FBLG a Nano Cap stock.